Ipamorelin Half-Life & Stability
Part of the full Ipamorelin guide - a selective growth-hormone secretagogue reference compound, identity-verified with a COA on every vial.
In brief
This spoke addresses pharmacokinetic, stability, degradation, and storage considerations for ipamorelin. Important scope note: the provided entry contains no ipamorelin-specific half-life, clearance, or stability numbers. Accordingly, this spoke draws on general peptide-class principles, clearly labeled as general, and uses only the structural facts present in the entry (the pentapeptide sequence and its non-coded residues) where peptide-specific reasoning is possible. No human pharmacokinetic figures are invented or asserted.
The detail
A closer look
01
What the entry does and does not provide
The entry supplies ipamorelin's class, sequence, molecular weight (711.86 g/mol), formula (C38H49N9O5), CAS number, mechanism, research areas, and one citation. It does not provide a measured half-life, plasma clearance rate, metabolic-pathway map, or quantitative stability data. Therefore any half-life or degradation statement below is presented as a general property of small synthetic peptides of this size class, not as a measured ipamorelin value. Where the molecule's own structure permits a qualitative inference, that is noted explicitly and tied to the entry's sequence data.
02
General peptide-class PK and degradation principles
As a general matter, small linear peptides in aqueous solution are subject to enzymatic and chemical degradation: peptidase and protease cleavage of backbone amide bonds, plus chemical routes such as oxidation, deamidation, and hydrolysis. Short peptides of this molecular-weight range are, as a class, typically cleared faster than large protein biologics. These are general statements about the peptide class; the entry provides no ipamorelin-specific rate, so no numeric half-life is given here.
03
Structure-based stability inferences from the entry
Two structural features in the entry data are relevant to general stability reasoning. First, the sequence is C-terminally amidated (the '-NH2' terminus in Aib-His-D-2-Nal-D-Phe-Lys-NH2); C-terminal amidation is, in general peptide chemistry, a modification that can reduce susceptibility to certain carboxypeptidase activity relative to a free acid terminus. Second, the molecule incorporates non-coded residues, aminoisobutyric acid (Aib, an alpha,alpha-disubstituted residue) and D-configuration residues (D-2-Nal, D-Phe). Non-proteinogenic and D-amino-acid substitutions are, as a general principle, often associated with altered recognition by standard proteases compared with all-L, all-coded peptides. These inferences follow from the entry's own sequence; they are qualitative structure-stability notes, not measured stability data for ipamorelin.
04
Storage implications for the laboratory
Following general peptide-class handling: the lyophilized solid is more stable than peptide in solution, so dry powder is kept cold, dry, and light-protected, while reconstituted solution is held refrigerated for short-term benchtop work and frozen for longer holds with minimized freeze-thaw cycling. Because the entry gives no ipamorelin-specific shelf-life or in-solution stability figure, no expiry interval is asserted; these are conservative general conventions applied to preserve peptide integrity for laboratory use.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Ipamorelin is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.